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OBJECTIVE
In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) cardiovascular (CV) outcomes trial (NCT01179048),
liraglutide significantly reduced the risk of CV events (by 13%) and hypoglycemia
versus placebo. This post hoc analysis examines the associations between hypo-
glycemia and CV outcomes and death.
RESEARCH DESIGN AND METHODS
Patients with type 2 diabetes and high risk for CV disease (n = 9,340) were
randomized 1:1 to liraglutide or placebo, both in addition to standard treatment,
and followed for 3.5–5 years. The primary end point was time to firstmajor adverse
cardiovascular event (MACE) (1,302 first events recorded), and secondary end
points included incidence of hypoglycemia.We used Cox regression to analyze time
to first MACE, CV death, non-CV death, or all-cause death with hypoglycemia as a
factor or time-dependent covariate.
RESULTS
A total of 267 patients experienced severe hypoglycemia (liraglutide n = 114,
placebo n = 153; rate ratio 0.69; 95% CI 0.51, 0.93). These patients had longer
diabetes duration, higher incidence of heart failure and kidney disease, and used
insulin more frequently at baseline than those without severe hypoglycemia. In
combined analysis (liraglutide and placebo), patients with severe hypoglycemia
were more likely to experience MACE, CV death, and all-cause death, with higher
risk shortly after hypoglycemia. The impact of liraglutide on risk of MACE was sim-
ilar in patients with and without severe hypoglycemia (P-interaction = 0.90).
CONCLUSIONS
Patients experiencing severe hypoglycemia were at greater risk of CV events and
death, particularly shortly after the hypoglycemic episode.While causality remains
unclear, reducing hypoglycemia remains an important goal in diabetes manage-
ment.
The clinical management of type 2 diabetes emphasizes the importance of glycemic
control to reduce the risk of diabetes-related complications (1). However, hypo-
glycemia remains a significant barrier to optimizing glucose control with some
glucose-lowering medications (1). In the context of macrovascular complications,
cardiovascular (CV) events are the leading cause of death among patients with
diabetes, and the risk of CV death for patients with diabetes is more than double that
for people without diabetes (2).
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In the Liraglutide Effect and Action in
Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) CV outcomes
trial, the glucagon-like peptide 1 analog
liraglutide was shown to significantly re-
duce CV events and mortality, compared
with placebo, when added to standard
of care in patients with type 2 diabetes
and high risk for CV events (3). Previous
randomized clinical trials of liraglutide
have demonstrated clinically significant
reductions in hyperglycemia and body
weight, with a low incidence of hypo-
glycemia (4–9). The Effect of Liraglutide
Versus Placebo When Added to Basal
Insulin Analogues With or Without Met-
formin in Subjects With Type 2 Diabetes
(LIRA-ADD2BASAL) trial showed reduc-
tions in HbA1c and body weight with
liraglutide added to basal insulin com-
pared with basal insulin alone; however,
minor hypoglycemia was more frequent
with liraglutide treatment (although no
severe hypoglycemia was reported) (10).
The authors noted that if the basal insulin
dose had been reduced when liraglutide
was added, this might have mitigated
the effect on minor hypoglycemia. Con-
sistent with this idea, in A Trial Compar-
ing the Efficacy and Safety of Insulin
Degludec/Liraglutide and Insulin Degludec
in SubjectsWith Type 2 Diabetes (DUAL II)
trial, when added to basal insulin (with
a concomitant early decrease in insulin
dose), liraglutide reduced HbA1c with no
increase in hypoglycemia compared with
basal insulin alone (insulin dose was the
same in both treatment groups at trial
end) (11). The rates of both confirmed
and severe hypoglycemia in the LEADER
trial were reduced in liraglutide-treated
patients, despite lower HbA1c levels,
compared with placebo-treated control
subjects (3).
Previous studies in people with dia-
betes have demonstrated an association
of hypoglycemia and an increased risk of
CV events and mortality (12–14). Mech-
anistically, this could involve hemody-
namic changes and reduced myocardial
perfusion, induction of arrhythmias or a
prothrombotic state, and release of in-
flammatory markers, although evidence
for a causal effect of hypoglycemia on
CV events and mortality is limited (14).
In this post hoc analysis, we examine
the associations between hypoglycemia
and CV outcomes and mortality in pa-
tients with type 2 diabetes in the LEADER
trial.
RESEARCH DESIGN AND METHODS
Design
LEADER (NCT01179048) was a double-
blind, randomized, placebo-controlled,
global trial conducted at 410 sites in 32
countries. Patients with type 2 diabetes
and high risk for CV events were ran-
domized 1:1 to receive liraglutide or
placebo, both in addition to standard-
of-care treatment, and followed for 3.5–
5 years. Detailed descriptions of the trial
design and methods have been published
previously (3,15).
End Points and Variables
The primary end point in LEADER was
time to the first occurrence of a major
adverse cardiovascular event (MACE),
a composite outcome consisting of CV
death, nonfatal MI, or nonfatal stroke.
Secondary end points included each in-
dividual component of the primary end
point and all-cause death.
Occurrence of self-reported hypogly-
cemia was a secondary safety end point
in LEADER and was reported using pa-
tient diaries and transcribed into the
case report form (CRF). Severe hypogly-
cemia was defined according to Amer-
ican Diabetes Association criteria as
hypoglycemia requiring the assistance
of another person to actively adminis-
ter carbohydrate, glucagon, or other re-
suscitative actions (16) and was reported
as a medical event of special interest in
the LEADER trial. Confirmed hypoglyce-
mia was defined as severe hypoglyce-
mia or minor hypoglycemia (defined as
plasma glucose,3.1 mmol/L [,56 mg/dL]
with or without symptoms). Nocturnal
hypoglycemia was defined as episodes
occurring between 00:01 and 05:59 h.
Patients were instructed to measure
blood glucose whenever a hypoglycemic
episode was suspected.
Other variables recorded included
insulin use, age, duration of diabetes,
glucose-lowering medication, HbA1c at
baseline, change in HbA1c from baseline,
and absolute HbA1c values at the time of
a hypoglycemic episode.
Statistical Analysis
We used Cox regression to analyze time
to the first MACE, CV death, non-CV
death, or all-cause death with either
severe hypoglycemia at any time (yes/no)
as a factor or with hypoglycemia (severe
or confirmed, yes/no) as a time-dependent
covariate adjusted for randomized
treatment. For each end point, an interac-
tion term between treatment and hypo-
glycemia was tested and removed if not
significant at the 5% significance level.
Patients were censored at the time from
randomization to the end point of interest,
to discontinuation, or to the follow-up visit
(scheduled 30 days after treatment end).
For the time-dependent analyses,
the patient’s status changed from non-
exposed to exposed at the time of a
hypoglycemic episode. In analyses in-
cluding fixed periods of follow-up (7–
365 days), the patient was considered to
be exposed to a hypoglycemic episode
at the time of the episode until the end
of the fixed period. Time-varying cova-
riates were introduced by dividing the
time between randomization and censor-
ing for each patient into distinct periods
demarcated by changes of the exposure
variables and the time-varying covariate.
Sensitivity analyses were performed
with adjustment for the following: 1)
baseline covariates (glucose-lowering
medication, sex, age, HbA1c, diabetes
duration); 2) concomitant insulin use
during the trial as a time-dependent
covariate; 3) HbA1c during the trial
(change from baseline and absolute val-
ues at the time of a hypoglycemic epi-
sode) as a time-dependent covariate;
4) concomitant sulfonylurea/glinide use
during the trial as a time-dependent
covariate; and 5) concomitant insulin
use, HbA1c, concomitant sulfonylurea/
glinide use, estimated glomerular filtra-
tion rate (eGFR) (change from baseline
and absolute values at the time of a
hypoglycemic episode), and event adju-
dication committee–confirmed hospi-
talization for heart failure during the
trial as time-dependent covariates.
As a supplementary analysis, time to
first MACE, CV death, non-CV death, all-
cause death and severe hypoglycemia
was analyzed using Cox regression with
the number of prior confirmed hypogly-
cemic episodes as a continuous time-
dependent covariate and randomized
treatment as a factor.
Descriptive statistics were calculated
for patient characteristics and the oc-
currence of hypoglycemia. The number
of hypoglycemic episodes was analyzed
using a negative binomial regression
model with a log link and the logarithm
of the observation time (100 years) as
offset. Treatment, sex, region, andglucose-
lowering medication at baseline were
included as fixed effects, and age at base-
line was included as a covariate.
Partial population-attributable risks
for exposure to severe hypoglycemia
(for MACE, CV death, non-CV death, or
all-cause death) were estimated using
the approximate method described by
Spielgelman et al. (17). We used time at
risk for severe hypoglycemia as an esti-
mate for the prevalence, and the hazard
ratios (HRs) from the time-varying Cox re-
gression model (with severe hypoglycemia
as a time-dependent variable, adjusted for
treatment) as plug-ins for the risk ratios.
RESULTS
Patient disposition, demographics, and
baseline characteristics have been de-
scribed previously (3). In summary, 9,340
patients with type 2 diabetes at high risk
for CV events were randomized to re-
ceive liraglutide (n = 4,668) or placebo
(n = 4,672), both in addition to standard-
of-care therapy (3). Median exposure to
study drug (liraglutide or placebo) was 3.5
years, andmediandurationof follow-upwas
3.8years (3).Atbaseline,patientshadamean
age of 64 years, mean BMI of 32.5 kg/m2,
mean HbA1c of 8.7% (72 mmol/mol), and
mean diabetes duration of 13 years. Over-
all, 64% of patients were male (3,15).
The primary outcome (MACE) occurred
in 608 of 4,668 patients (13%) in the
liraglutide group and in 694 of 4,672




A total of 267 patients (3%) experienced
433 episodes of severe hypoglycemia
during the trial (3). At baseline, these
patients were older, had a longer dura-
tion of diabetes, tended to have worse
renal function (eGFR), had more heart
failure (New York Heart Association class
II–III), and used insulin more frequently
compared with patients without severe
hypoglycemia (Table 1). Other baseline
characteristics, including HbA1c, were
similar across the two groups (Table 1).
A total of 4,169 patients (45%) expe-
rienced 27,933 episodes of confirmed
hypoglycemia during the trial. These
patients had a longer duration of diabe-
tes and lower body weight, tended to
have worse renal function (eGFR), and
more frequently used insulin at baseline
than those who did not experience con-
firmed hypoglycemia (Table 1).
Nocturnal severe hypoglycemia was
reported by 59 of 267 patients (22%)
who experienced severe hypoglycemia,
representing 21% (90/433) of all severe
episodes. Nocturnal confirmed hypogly-
cemia represented 18% (5,150/27,933)
of all confirmed episodes.
Treatment Effects on Hypoglycemia
Rates of severe and confirmed hypogly-
cemia during the trialwere higher among
patientsusing insulinatbaselinecompared
with those patients using other or no
glucose-lowering medication at baseline
and those patients who initiated insulin
after baseline (Supplementary Table 1).
As previously reported, the rates of
severe and confirmed hypoglycemia
were significantly lower in the liraglutide-
treated versus placebo-treated group
(3), and these beneficial effects in-
creased over time (Fig. 1). Further-
more, the rates of severe and confirmed
hypoglycemia remained lower among
liraglutide-treated versus placebo-treated
patients irrespective of baseline glucose-
lowering medication (insulin, sulfonylureas,
or glinides) (Supplementary Table 2).
The rates of nocturnal severe and noc-
turnal confirmed hypoglycemia were
also lower in the liraglutide-treated ver-
sus placebo-treated group, but the
treatment difference was not statisti-
cally significant for nocturnal severe
hypoglycemia.
Among patients initiating insulin ther-
apy after baseline, those treated with
liraglutide were at lower risk of a severe
hypoglycemic episode after insulin initia-
tion compared with those in the placebo-
treated group, but this difference was not
statistically significant (HR 0.7; 95% CI 0.3,
1.3; P = 0.24).
Association of Severe Hypoglycemia
With CV Outcomes and Mortality
In total, 66 of 1,302 (5%) first MACE
recorded in the trial occurred in patients
who experienced severe hypoglycemia
(at any time during the trial). Patients
who experienced severe hypoglycemia
during the trial were more likely than
those without severe hypoglycemia to
experience MACE, CV death, non-CV
death, or all-cause death (P , 0.001 for
all four outcomes) (Fig. 2). Similar results
were observed irrespective of insulin,
sulfonylurea, or glinide use, although not
all associations were statistically signif-
icant (Supplementary Tables 3–5).
Furthermore, a temporal association
between severe hypoglycemic episodes
and subsequent risk of MACE, CV death,
non-CV death, or all-cause death was
identified (Fig. 2). This temporal associ-
ation was strongest shortly after a hy-
poglycemic episode, with a pattern of
increasing risk for MACE, CV death, non-
CV death, or all-cause death in the
shorter follow-up periods after severe
hypoglycemia (Fig. 2). In the 7 days fol-
lowing a severe hypoglycemic episode,
patients were at 7- to 15-fold higher risk
of MACE, CV death, non-CV death, or
all-cause death than those patients with-
out severe hypoglycemia (Fig. 2).
These associations between severe
hypoglycemia and MACE, CV death,
non-CV death, and all-cause death re-
mained significant when adjusted for
relevant covariates including glucose-
lowering medication, sex, age, HbA1c,
and diabetes duration at baseline as
well as concomitant insulin and sulfonyl-
urea/glinide use, HbA1c, eGFR, and hos-
pitalization for heart failure during the
trial (Supplementary Fig. 1).
The estimated risk of MACE, CV
death, non-CV death, or all-cause death
attributable to severe hypoglycemia was
between 1 and 3% (partial population-
attributable risks: MACE 1.1% [95% CI
0.4, 1.8], CV death 3.2% [95% CI 1.5, 4.9],
non-CV death 2.3% [95% CI 0.4, 4.1],
all-cause death 2.8% [95% CI 1.6, 4.1]).
Similar to patients who experienced
severe hypoglycemia, those who ex-
perienced nocturnal severe episodes
during the trial were more likely than
patients who did not to experience
MACE (HR 2.1; 95% CI 1.3, 3.4; P =
0.0039) or CV death (HR 2.7; 95% CI 1.3,
5.4; P = 0.0058). There were no signif-
icant differences in the risk of non-CV
death (HR 0.5; 95% CI 0.1, 3.6; P = 0.50) or
all-cause death (HR 1.8; 95% CI 0.9, 3.5;
P = 0.07) between patients who experi-
enced nocturnal severe hypoglycemia
and those who did not.
Association of Confirmed
Hypoglycemia With CV Outcomes,
Mortality, and Severe Hypoglycemia
When analyzed using the Cox regression
model with confirmed hypoglycemia
(yes, no) as a time-dependent covariate,
patients who experienced confirmed hy-
poglycemia were found to be at higher
risk of non-CV death compared with
those who did not (HR 1.40; 95% CI
1.12, 1.74), but there was no significant
difference in the risk for MACE (HR 1.07;
95% CI 0.95, 1.20), CV death (HR 0.98;
95% CI 0.82, 1.18), or all-cause death
(HR 1.13; 95% CI 0.98, 1.31).
However, when analyzed according
to the number of prior confirmed hy-
poglycemic episodes, each confirmed
episode significantly increased the sub-
sequent risk of all-cause death (HR 1.01;
95% CI 1.00, 1.02) and severe hypogly-
cemia (HR 1.03; 95% CI 1.02, 1.03).
Numerically increased risks for MACE
(HR 1.01; 95% CI 1.00, 1.01), CV death
(HR 1.01; 95% CI 1.00, 1.02), and non-CV
Table 1—Baseline characteristics of patients with and without hypoglycemia during the trial
Severe hypoglycemia Confirmed hypoglycemia
Yes (n = 267) No (n = 9,073) Yes (n = 4,169) No (n = 5,171)
Male 166 (62.2) 5,837 (64.3) 2,631 (63.1) 3,372 (65.2)
Age, years 66.4 6 7.7 64.2 6 7.2 64.6 6 7.2 64.0 6 7.3
Diabetes duration, years 16.0 6 8.3 12.7 6 8.0 14.6 6 8.4 11.4 6 7.4
Insulin use 180 (67.4) 3,989 (44.0) 2,321 (55.7) 1,848 (35.7)
Geographic region
Europe 83 (31.1) 3,213 (35.4) 1,300 (31.2) 1,996 (38.6)
North America 96 (36.0) 2,751 (30.3) 1,329 (31.9) 1,518 (29.4)
Asia 17 (6.4) 694 (7.6) 319 (7.7) 392 (7.6)
Rest of the world 71 (26.6) 2,415 (26.6) 1,221 (29.3) 1,265 (24.5)
HbA1c, % 8.8 6 1.7 8.7 6 1.5 8.7 6 1.5 8.7 6 1.6
HbA1c, mmol/mol 72.9 6 18.9 71.5 6 16.6 71.4 6 16.3 71.6 6 17.0
BMI, kg/m2 32.3 6 6.4 32.5 6 6.3 32.0 6 6.2 32.9 6 6.3
Body weight, kg 90.4 6 22.5 91.8 6 20.9 89.7 6 20.6 93.4 6 21.2
Systolic blood pressure, mmHg 137.8 6 20.7 135.8 6 17.6 135.3 6 18.2 136.4 6 17.4
Diastolic blood pressure, mmHg 75.5 6 10.1 77.1 6 10.2 76.1 6 10.3 77.9 6 10.1
Heart rate, bpm 73.4 6 12.0 72.6 6 11.4 72.3 6 11.5 72.9 6 11.2
CV medication
Antihypertensive therapy 255 (95.5) 8,376 (92.3) 3,914 (93.9) 4,717 (91.2)
b-Blockers 146 (54.7) 5,035 (55.5) 2,389 (57.3) 2,792 (54.0)
Diuretics 151 (56.6) 3,755 (41.4) 1,857 (44.5) 2,049 (39.6)
Statins 196 (73.4) 6,545 (72.1) 3,177 (76.2) 3,564 (68.9)
Platelet aggregation inhibitors 174 (65.2) 6,152 (67.8) 2,976 (71.4) 3,350 (64.8)
Established CVD (age $50 years) 229 (85.8) 7,369 (81.2) 3,456 (82.9) 4,142 (80.1)
Prior myocardial infarction 89 (33.3) 2,775 (30.6) 1,347 (32.3) 1,517 (29.3)
Prior stroke or transient ischemic attack 51 (19.1) 1,456 (16.0) 686 (16.5) 821 (15.9)
Prior revascularization 108 (40.4) 3,530 (38.9) 1,730 (41.5) 1,908 (36.9)
.50% stenosis of coronary, carotid, or
lower-extremity arteries 60 (22.5) 2,319 (25.6) 1,115 (26.7) 1,264 (24.4)
Documented symptomatic CHD* 16 (6.0) 802 (8.8) 349 (8.4) 469 (9.1)
Documented asymptomatic cardiac ischemia† 60 (22.5) 2,412 (26.6) 1,093 (26.2) 1,379 (26.7)
Heart failure NYHA II–III 56 (21.0) 1,249 (13.8) 559 (13.4) 746 (14.4)
Chronic kidney disease‡ 119 (44.6) 2,188 (24.1) 1,245 (29.9) 1,062 (20.5)
CVD risk factors (age $60 years) 38 (14.2) 1,704 (18.8) 713 (17.1) 1,029 (19.9)
Microalbuminuria or proteinuria 26 (9.7) 1,033 (11.4) 459 (11.0) 600 (11.6)
Hypertension and left ventricular hypertrophy 8 (3.0) 491 (5.4) 193 (4.6) 306 (5.9)
Left ventricular systolic or diastolic dysfunction 6 (2.2) 388 (4.3) 160 (3.8) 234 (4.5)
Ankle-brachial index ,0.9 10 (3.7) 216 (2.4) 88 (2.1) 138 (2.7)
Renal function, eGFR mL/min/1.73 m2
Normal ($90) 67 (25.1) 3,208 (35.4) 1,228 (29.5) 2,047 (39.6)
Mild impairment (60–89) 82 (30.7) 3,825 (42.2) 1,767 (42.4) 2,140 (41.4)
Moderate impairment (30–59) 96 (36.0) 1,838 (20.3) 1,036 (24.9) 898 (17.4)
Severe impairment (,30) 22 (8.2) 202 (2.2) 138 (3.3) 86 (1.7)
Creatinine, mmol/L 108.4 6 63.2 86.8 6 38.3 92.3 6 42.4 83.5 6 36.4
Albumin/creatinine ratio, mg/g 536.9 6 1,482.8 180.1 6 874.3 217.6 6 730.8 168.2 6 1,014.3
Alanine aminotransferase, units/L 23.8 6 14.1 26.8 6 16.2 25.8 6 15.7 27.6 6 16.4
Bilirubin, mmol/L 7.3 6 4.2 7.8 6 4.2 7.5 6 3.9 8.1 6 4.4
Sodium, mmol/L 140.1 6 2.8 140.0 6 2.7 140.1 6 2.7 139.9 6 2.7
Potassium, mmol/L 4.6 6 0.5 4.5 6 0.5 4.5 6 0.5 4.5 6 0.5
Values are mean 6 SD or number of patients (proportion of patients with or without severe or confirmed hypoglycemia [%]). CHD, coronary heart
disease; CVD, cardiovascular disease; NYHA, New York Heart Association. *Positive exercise stress test or any cardiac imaging or unstable
angina with electrocardiogram changes. †Positive nuclear imaging test, exercise test, or dobutamine stress echo. ‡eGFR ,60 mL/min/1.73 m2 per
MDRD formula or Cockcroft-Gault formula.
death (HR 1.01; 95% CI 1.00, 1.02) were
also observed but were not statistically
significant.
Protective Interaction Between
Liraglutide Treatment and Severe
Hypoglycemia
The protective effect of liraglutide on
risk of first MACE in LEADER reported
previously (3) was similar in patients
with or without severe hypoglycemia
(P-interaction = 0.90) (Table 2). Similar
results were observed for CV death and
all-cause death.
The association between severe hy-
poglycemia andMACE, CV death, non-CV
death, or all-cause death was unaffected
by treatment with liraglutide or placebo:
no interaction was identified between
randomized treatment and severe hypo-
glycemia (P-interaction = nonsignificant
for all four outcomes). There was also no
interaction identified after adjustment
for covariates including glucose-lowering
medication, sex, age, HbA1c, and dia-
betes duration at baseline as well as
concomitant insulin use and HbA1c as
time-dependent covariates during the
trial.
CONCLUSIONS
This post hoc analysis has demonstrated
an association between the occurrence of
severe hypoglycemia and an increased
risk of CV events and mortality in the
overall LEADER trial population (irre-
spective of randomized treatment).
The association was maintained after
correction for important variables at
baseline and during the study. We
have also shown a temporal relationship
between the risk of CV events and death
after a severe hypoglycemic episode,
with event rates being higher closer to
the episode. These findings further sup-
port the associations between severe
hypoglycemia and the risk of CV events
and mortality described in recent liter-
ature (12–14,18–21), with this associa-
tion becoming more robust and with a
stronger temporal relationship, albeit
with a small attributable risk. These
results demonstrate the potentially se-
rious implications of severe hypoglyce-
mia on CV events and naturally raise
questions as to how clinical practice
can lower this burden and manage
patients effectively after severe hypogly-
cemic episodes in the short- and long-
term. There is currently noclear guidance
for managing such patients.
Our analysis advances the literature
by showing the temporal association be-
tween severe hypoglycemia and CV out-
comes and mortality in type 2 diabetes:
the risk of these outcomes increased with
shorter follow-up periods after a severe
hypoglycemic episode. There was a pla-
teau effect in the trend for increasing risk
closer to the hypoglycemic episode ob-
served with fewer than 30 days of follow-
up. This could arise from an incubation
period after the episode, before the ef-
fect manifests, but we believe that it is
more likely to result from a low number
of events and consequential lack of pre-
cision in the HRs (large CIs) after 7 and
15 days of follow-up. A subanalysis of the
smaller Examination of Cardiovascular
Outcomes with Alogliptin versus Stan-
dard of Care (EXAMINE) CV outcomes
trial (n = 5,380) identified an association
between hypoglycemia and risk of MACE,
but the association was no longer signif-
icant when considering a temporal as-
sociation (MACE after hypoglycemic
episodes) (18). Similarly, analysis of
the Action in Diabetes and Vascular
Disease: Preterax and Diamicron MR
Controlled Evaluation (ADVANCE) trial
(n = 11,140) showed strong associa-
tions between severe hypoglycemia
and a range of clinical outcomes includ-
ing CVevents anddeath, but no temporal
association was identified (19). Analyses
from the Outcome Reduction With Initial
Glargine Intervention (ORIGIN) trial (n =
12,537) also showed increased risks of
CV events and death in patients who
experienced severe hypoglycemia (20).
These associations remained significant
after adjusting for a severe hypoglyce-
mia propensity score and for outcomes
that occurred within 1 or 7 days follow-
ing a severe hypoglycemic episode (20).
Results from the Trial Evaluating Car-
diovascular Outcomes With Sitagliptin
(TECOS) (n = 14,671) have confirmed the
association between severe hypoglyce-
mia and subsequent CV events (21).
Recent analysis of the Trial Comparing
Cardiovascular Safety of Insulin Degludec
Figure 1—Severe (A) and confirmed (B) hypoglycemia over time among patients treated with
liraglutide or placebo. Severe hypoglycemia was defined according to American Diabetes
Association criteria as hypoglycemia requiring the assistance of another person to actively
administer carbohydrate, glucagon, or other resuscitative actions (16). Confirmed hypoglycemia
was defined as severe hypoglycemia or minor hypoglycemia (defined as plasma glucose
,3.1 mmol/L [,56 mg/dL] with or without symptoms). The number of episodes was analyzed
using a negative binomial regression model with a log link and the logarithm of the observation
time (100 years) as offset.
Versus Insulin Glargine in Subjects With
Type 2 Diabetes at High Risk of Cardio-
vascular Events (DEVOTE) trial (n = 7,637)
is largely in agreement with our analysis,
showing a higher risk of all-cause mor-
tality in patients experiencing severe
hypoglycemia when examining tempo-
ral associations, although no association
was found between severe hypoglycemia
and CV events (22).
The associations we have shown be-
tween severe hypoglycemia and CV out-
comes and mortality were robust and
were maintained after correction for
important variables that could confound
the results, including insulin use and
change in HbA1c. After analyzing the
association of hypoglycemia and CV
andmortality outcomes in the ADVANCE
trial, it was noted that the associations
were markedly attenuated after adjust-
ment for potential confounders, and the
Figure 2—Association between severe hypoglycemia and CV events and death. Risk of outcome with event and severe hypoglycemia at any time
is based on analysis of time to first MACE, CV death, non-CV death, or all-cause death, using Cox regression with severe hypoglycemia (yes/no) at
any time as a factor. Risk of outcomewith events after severe hypoglycemia is basedon severe hypoglycemic episodes prior toMACE, CVdeath, non-CV
death, or all-cause death, using a time-dependent covariate Cox regression: all events (follow-up until last contact date), follow-up within 7, 15, 30,
60, 90, 180, and 365 days. *P , 0.05; **P , 0.001; ***P , 0.0001.
Table 2—MACE according to severe hypoglycemia and treatment group
Patient population
Liraglutide Placebo
HR (95% CI) P-interactionn MACE* n MACE*
All 4,668 608 4,672 694 0.87 (0.78, 0.97)
With severe
hypoglycemia 114 26 153 40 0.85 (0.52, 1.39) 0.90
Without severe
hypoglycemia 4,554 582 4,519 654 0.88 (0.78, 0.98)
HRs were estimated with the use of a Cox proportional hazards model with treatment as
a covariate. *First MACE (CV death, nonfatal myocardial infarction, or nonfatal stroke).
authors suggested that along with the
absence of a temporal relationship, this
indicated that severe hypoglycemia was
unlikely to have a direct causal role in CV
events and mortality (19). Similarly, the
associations between severe hypoglyce-
mia and subsequent CV events in TECOS
were not apparent in fully adjusted mod-
els (21). In combination with a converse
relationship between CV events and
subsequent severe hypoglycemia (main-
tained in fully adjusted models), this led
the authors to conclude that severe
hypoglycemia and CV events are com-
mon markers of at-risk, frail patients
(21). Compared with the results from
ADVANCE, ORIGIN, TECOS, and DEVOTE,
we have shown more distinct temporal
relationships between severe hypogly-
cemia and CV and mortality outcomes
that are maintained after adjusting for
confounders (19–22). However, while
our findings differ from those of the
ADVANCE and TECOS analyses, it is un-
clear whether our results represent a
direct effect of severe hypoglycemia;
hence, we cannot rule out the possi-
bility that severe hypoglycemia is a
marker of frail and vulnerable patients
(14,19,21).
Beyond randomized clinical trial data,
there is recent epidemiological evidence
for the association of severe hypoglyce-
mia and CV disease and mortality from
the Atherosclerosis Risk in Communities
(ARIC) study (23). This study also found
that the association between severe
hypoglycemia and CV events was stron-
ger in the first year for those events with
an atherosclerotic pathophysiology (23).
This supports atherosclerosis as a pos-
sible mechanism, which could be induced
by an increase in platelet aggregation and
the release of inflammatory cytokines
as a direct causal effect of severe hypo-
glycemia on the risk of CV events (23,24).
In contrast to the clear association
between severe hypoglycemia and CV
outcomes and mortality, the relationship
between confirmed hypoglycemia (se-
vere or minor hypoglycemia) and these
outcomes is less straightforward. While
the occurrence of severe hypoglycemia
increased the risk of CV outcomes and
mortality, the occurrence of confirmed
hypoglycemia appeared to have a neutral
effect on CV mortality and MACE. This is
in line with other studies reporting a
clear association with severe hypoglyce-
mia but without a significant effect of
nonsevere hypoglycemia on CV or all-
cause mortality (14).
A linear relationship was observed
between the number of confirmed hy-
poglycemic episodes and the risk of
all-cause death, with each confirmed
episode increasing the risk of death.
The effect of a single confirmed hypo-
glycemic episode on the risk of all-cause
death was modest, but the increased
risk corresponded to ;9% for a patient
experiencing 10 confirmed hypoglyce-
mic episodes. Similar associations were
also observed for MACE, CV death, and
non-CV death, but the increased risks
were not statistically significant. Fur-
thermore, there was also an increased
risk of severe hypoglycemia associated
with an increasing burden of confirmed
hypoglycemia, in line with the hypothe-
sis that episodes of severe hypoglyce-
mia act as a marker or manifestation of
frequent, recurrent, but less severe hy-
poglycemic episodes that may lead to
death (25). Overall, the results of our
analyses show that episodes of severe
and confirmed hypoglycemia are as-
sociated with increased risks for ad-
verse CV and mortality outcomes, albeit
with stronger associations for severe
hypoglycemia.
Patients experiencing hypoglycemia
in the LEADER trial had worse renal func-
tion and more frequently used insulin
at baseline than those patients who did
not experience hypoglycemia. Higher
age, longer duration of diabetes, and
greater frequency of heart failure at
baseline also highlighted the patients
who experienced severe versus con-
firmed hypoglycemia, supporting the
notion that these populations represent
different patients or at least that those
experiencing severe hypoglycemia are a
distinct subgroup.
Treatment with liraglutide reduced
hypoglycemia in the LEADER trial com-
pared with placebo (3). This is in agree-
ment with previous results showing a
protective effect of liraglutide on insulin-
induced hypoglycemia (11). Approx-
imately one-fifth of hypoglycemic epi-
sodes (severe and confirmed) in the
LEADER trial were classified as noc-
turnal, and we have shown that these
were also reduced with liraglutide treat-
ment (albeit the reduction was not sta-
tistically significant for nocturnal severe
hypoglycemia). This finding may be par-
ticularly pertinent due to the clinical
impact these episodes can have on hy-
poglycemia unawareness, counterregu-
latory responses and glycemic control,
daily well-being, and sleep (26–29).
The beneficial effects on hypoglycemia
in liraglutide-treated patients increased
over time, and given that hypoglycemia
increases with duration of insulin use
(30), this may reflect the reduced require-
ment for insulin in liraglutide-treated pa-
tients during the trial compared with
placebo-treated patients (3).
The mechanisms underlying the car-
dioprotective effects of liraglutide in the
LEADER trial are unknown, but the as-
sociation between severe hypoglycemia
and CV and mortality outcomes, along
with the reduction in severe hypoglyce-
mia observed with liraglutide, could be
contributing factors. However, even if
severe hypoglycemia has a causal effect
on CV events and mortality, attributable
risk calculations suggested that prevent-
ing severe hypoglycemia could have only
modestly reduced the incidence of CV
and mortality outcomes (reductions of
8–23 events for the CV andmortality end
points analyzed). Thus, while reducing se-
vere hypoglycemia may contribute to
the cardioprotective effects of liraglutide,
it could not alone represent the key
mechanism. Furthermore, there was no
treatment interaction with severe hypo-
glycemia for the CV and mortality end
points analyzed.
In addition to the LEADER trial, three
other CV outcomes trials, Empagliflozin
Cardiovascular Outcome Event Trial in
Type2DiabetesMellitusPatients (EMPA-
REG OUTCOME), the CANagliflozin car-
dioVascular Assessment Study (CANVAS)
Program, and Trial to Evaluate Cardio-
vascular and Other Long-term Out-
comes With Semaglutide in Subjects
With Type 2 Diabetes (SUSTAIN-6)
(post hoc analysis), have recently re-
ported beneficial effects on CVoutcomes
with the sodium–glucose cotransporter
2 inhibitors empagliflozin and canagli-
flozin as well as the glucagon-like pep-
tide 1 analog semaglutide, respectively
(relative to placebo, in addition to stan-
dard care) (31–33). No differences in
the occurrence of hypoglycemia be-
tween active treatment and placebo
were found in these trials, suggesting
that other mechanisms were responsi-
ble for the reduction in CV risk (31–33).
Nevertheless, the importance of reduced
severe hypoglycemia, as observed with
liraglutide, remains high due to the asso-
ciation with major CV events and death
as well as more direct consequences
such as compromised physical, mental,
and social functioning and reduced qual-
ity of life (34).
Limitations
When interpreting the results of this
analysis, it is important to remember
that it was conducted post hoc without
adjustment for multiple comparisons
and that it is based on self-reporting
of hypoglycemia using patient diaries
with details transcribed into CRFs. This
process could lead to underreporting of
hypoglycemia, particularly in the period
between the last CRF update and a death.
With a further requirement for reporting
of severe hypoglycemia as a medical
event of special interest, we suggest
that severe episodes are less susceptible
to this issue than confirmed hypogly-
cemic episodes. Other studies have
adjudicated hypoglycemic episodes or
reported severe episodes leading to hos-
pitalization (25,35). Studies using contin-
uous glucose monitoring suggest that
self-reporting of hypoglycemia underes-
timates the true incidence of hypogly-
cemia, particularly during the nocturnal
period (36). Although the associations
between severe hypoglycemia and CV
events and mortality appear robust, the
risk of these events attributable to severe
hypoglycemia was small. It should also be
noted that the analyses indicating that
liraglutide has the same effect on CV
outcomes and mortality in patients both
with and without severe hypoglycemia
are limited by the inclusion of postran-
domization covariates. Furthermore, it
has been proposed that hypoglycemia
may trigger CV events in patients already
at risk (14), and the high–CV risk patient
population from the LEADER trial may
limit the application of these results to
other patients with diabetes.
Summary
In summary, patients experiencing se-
vere hypoglycemia in LEADER were at
greater risk of MACE, CV death, non-CV
death, and all-cause death than patients
who did not experience severe hypogly-
cemia. This may warrant specific clinical
attention and treatment, particularly in
the time shortly after a hypoglycemic
episode, to reduce the risk of these
serious events. Although the precise
impact of different treatments is unclear,
with the cardioprotective effects of
liraglutide appearing largely independent
of reductions in hypoglycemia, minimiz-
ing the risk of hypoglycemia is clearly an
important goal in diabetesmanagement.
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